Source: Flickr user Simon & His Camera .Love is in the air. At least it is for three of our top Motley Fool healthcare contributors. Each has a crush on a different biotech stock darling, and they all find their pick attractive for different reasons. Read on to learn which biotech companies have caught the fancy of these three contributors, […]
It’s been shown that dividend-paying stocks outperform their non-dividend paying counterparts, but focusing on dividends may not be the best strategy when it comes to big biotech stocks. Read on to learn why three Motley Fool contributors don’t think it makes sense for these big biotech companies to pay investors a dividend.Cheryl Swanson : Take a little trip through history […]
It remains a time for caution. After a brief flurry of optimism this Monday the rest of the week went quite badly. Friday the indexes opened mixed, sold off until mid day, tried to rally til mid afternoon, and then a flurry of selling into the close. Not great. The S&P 500 fell 1.30% and the NASDAQ 1.03%. A lower […]
LONDON, January 28, 2015 /PRNewswire/ –Investor-Edge has initiated coverage on the following equities: Halozyme Therapeutics Inc. (NASDAQ: HALO), Agenus Inc. (NASDAQ: AGEN), Biogen Idec Inc. (NASDAQ: BIIB), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), and Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM). Free research report on Halozyme Therapeutics can be accessed at http://get.Investor-Edge.com/pdf/?c=Halozyme%20Therapeutics&d=28-Jan-2015&s=HALO. On Tuesday, January 27, 2015, the NASDAQ Composite ended at 4,681.50, […]
View gallery.Biotech is big, and the industry has been big for quite some time.As a matter of fact, biotechnology has been the second-best performing industry over the last two years.Biotech stocks obviously come in all different shapes and sizes. Some investors like the small-caps, others prefer the middle of the road mid-caps.However, at the end of the day, the big […]
Sovaldi pill. Source: Gilead SciencesGilead Sciences had another phenomenal year in 2014, returning 26% for investors. That’s more than double the return of the broad-based S&P 500 , and it has hepatitis C drug Sovaldi to thank.In just the first nine months of 2014, Sovaldi netted Gilead $8.55 billion in sales. It’s the most effective drug launch in history by […]
By Ben LevisohnRBC’s Michael Yee and team explain why Celgene (CELG), Biogen Idec (BIIB), Vertex Pharmaceuticals (VRTX), BioMarin Pharmaceutical (BMRN) and Regeneron Pharmaceuticals (REGN) are their top biotech stocks for 2015:
Bloomberg News
Top-five longs: Celgene, Biogen Idec, BioMarin Pharmaceutical, Vertex Pharmaceuticals, Regeneron Pharmaceuticals: 1) Celgene we predict “settlement” with Actavis (ACT) could happen after spring when expert discovery ends and before Court begins mid-15; plus investors should start giving […]
View gallery.Many biotech stocks have been breaking out over the past two months.Newlink Genetics Corp and Incyte Corporation both skyrocketed in October.After that, stocks of Ariad Pharmaceuticals, Inc. and Celldex Therapeutics, Inc. both had nice, quick pops last month.Then there was Kite Pharma Inc’s huge jump earlier this month.
So, Who’s Next?
The Company: Sangamo Biosciences, Inc.Ticker Symbol: (NASDAQ: SGMO)Sector: HealthcareIndustry: BiotechnologySangamo focuses on the research, development and […]
Mergers and acquisitions show no signs of slowing down in the biotech sector with a $3.5 billion acquisition agreement being announced. Meanwhile, Biogen (BIIB – Analyst Report) is advancing towards developing a treatment for Alzheimer’s disease.Recap of the Week’s Most Important Stories1. Biogen is set to move its experimental Alzheimer’s disease treatment, BIIB037, into late-stage testing based on promising interim […]
In a market that is infused with headwinds coming from China, Russia and Europe, there is always one group that Jim Cramer can count on: Biotech.In fact, Cramer has been in a heated love affair with biotech for more than 30 years. While you don’t get a rally from them every day, he thinks they are more reliable than any […]
